Retatrutide: The Triple Agonist Transforming Obesity Treatment
Introduction Obesity is one of the most pressing health challenges of our time, affecting over 650 million adults worldwide. While lifestyle interventions remain the foundation of treatment, the past decade has seen a revolution in pharmacological therapies. GLP‑1 receptor agonists like semaglutide (Ozempic, Wegovy) and dual agonists like tirzepatide (Mounjaro, Zepbound) have already reshaped the…
